Patents by Inventor Alan P. Farwell

Alan P. Farwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-NUCLEAR EFFECTS OF THYROID HORMONE
    Publication number: 20080234365
    Abstract: Truncated thyroid hormone receptors ?TR?1 and ?TR?2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of ?TR?1 and ?TR?2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.
    Type: Application
    Filed: May 20, 2008
    Publication date: September 25, 2008
    Inventors: Jack L. Leonard, Alan P. Farwell
  • Methods for identifying compounds that modulate ?TR?2 activity
    Patent number: 7374890
    Abstract: Truncated thyroid hormone receptors ?TR?1 and ?TR?2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of ?TR?1 and ?TR?2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: May 20, 2008
    Assignee: University of Massachusetts
    Inventors: Jack L. Leonard, Alan P. Farwell
  • Non-nuclear effects of thyroid hormone
    Publication number: 20040265918
    Abstract: Truncated thyroid hormone receptors &Dgr;TR&agr;1 and &Dgr;TR&agr;2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of &Dgr;TR&agr;1 and &Dgr;TR&agr;2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.
    Type: Application
    Filed: April 12, 2004
    Publication date: December 30, 2004
    Applicant: University of Massachusetts, a Massachusetts corporation
    Inventors: Jack L. Leonard, Alan P. Farwell
  • Non-nuclear effects of thyroid hormone
    Patent number: 6730472
    Abstract: Truncated thyroid hormone receptors &Dgr;TR&agr;1 and &Dgr;TR&agr;2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of &Dgr;TR&agr;1 and &Dgr;TR&agr;2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: May 4, 2004
    Assignee: University of Massachusetts
    Inventors: Jack L. Leonard, Alan P. Farwell
  • Non-nuclear effects of thyroid hormone
    Publication number: 20020090604
    Abstract: Truncated thyroid hormone receptors &Dgr;TR&agr;1 and &Dgr;TR&agr;2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of &Dgr;TR&agr;1 and &Dgr;TR&agr;2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.
    Type: Application
    Filed: June 28, 2001
    Publication date: July 11, 2002
    Inventors: Jack L. Leonard, Alan P. Farwell